Published in J Am Soc Nephrol on October 01, 1999
Pros and cons for C4d as a biomarker. Kidney Int (2012) 2.03
De novo production of K-alpha1 tubulin-specific antibodies: role in chronic lung allograft rejection. J Immunol (2008) 1.95
Detection of C3d-binding donor-specific anti-HLA antibodies at diagnosis of humoral rejection predicts renal graft loss. J Am Soc Nephrol (2014) 1.60
Acute renal endothelial injury during marrow recovery in a cohort of combined kidney and bone marrow allografts. Am J Transplant (2011) 1.38
Anti-MHC class I antibody activation of proliferation and survival signaling in murine cardiac allografts. J Immunol (2008) 1.33
Diagnosis and management of antibody-mediated rejection: current status and novel approaches. Am J Transplant (2014) 1.29
Antibody-mediated rejection in kidney transplantation: a review. J Transplant (2012) 1.12
Four stages and lack of stable accommodation in chronic alloantibody-mediated renal allograft rejection in Cynomolgus monkeys. Am J Transplant (2008) 1.11
A signature of maternal anti-fetal rejection in spontaneous preterm birth: chronic chorioamnionitis, anti-human leukocyte antigen antibodies, and C4d. PLoS One (2011) 1.10
Implications for human leukocyte antigen antibodies after lung transplantation: a 10-year experience in 441 patients. Chest (2013) 1.08
Red blood cell age and potentiation of transfusion-related pathology in trauma patients. Transfusion (2011) 1.05
C4d deposition without rejection correlates with reduced early scarring in ABO-incompatible renal allografts. J Am Soc Nephrol (2008) 1.04
C4d as a Diagnostic Tool in Proliferative GN. J Am Soc Nephrol (2015) 1.03
Complement regulation of T cell immunity. Immunol Res (2012) 0.95
Pathologic findings in lung allografts with anti-HLA antibodies. J Heart Lung Transplant (2013) 0.93
The classical complement pathway in transplantation: unanticipated protective effects of C1q and role in inductive antibody therapy. Am J Transplant (2008) 0.92
Utility of renal allograft biopsy: An audit of 80 allograft biopsies. Indian J Nephrol (2013) 0.91
Molecules Great and Small: The Complement System. Clin J Am Soc Nephrol (2015) 0.91
The role of complement in membranous nephropathy. Semin Nephrol (2013) 0.90
Anti-complement component C5 mAb synergizes with CTLA4Ig to inhibit alloreactive T cells and prolong cardiac allograft survival in mice. Am J Transplant (2011) 0.90
Role of complement and NK cells in antibody mediated rejection. Hum Immunol (2012) 0.89
Complement as a multifaceted modulator of kidney transplant injury. J Clin Invest (2014) 0.89
Increased erythrocyte C4D is associated with known alloantibody and autoantibody markers of antibody-mediated rejection in human lung transplant recipients. J Heart Lung Transplant (2010) 0.88
Mechanisms involved in antibody- and complement-mediated allograft rejection. Immunol Res (2010) 0.88
Chronic alloantibody mediated rejection. Semin Immunol (2011) 0.87
Pathways to acute humoral rejection. Am J Pathol (2004) 0.87
An experimental model of acute humoral rejection of renal allografts associated with concomitant cellular rejection. Am J Pathol (2008) 0.87
Antibody-mediated rejection: emergence of animal models to answer clinical questions. Am J Transplant (2010) 0.87
Maternal floor infarction/massive perivillous fibrin deposition: a manifestation of maternal antifetal rejection? Am J Reprod Immunol (2013) 0.86
Evolving paradigms that determine the fate of an allograft. Am J Transplant (2010) 0.86
Partial therapeutic response to Rituximab for the treatment of chronic alloantibody mediated rejection of kidney allografts. Transpl Immunol (2012) 0.84
Thrombotic microangiopathy and peritubular capillary C4d expression in renal allograft biopsies. Clin J Am Soc Nephrol (2010) 0.84
Human leukocyte antigen antibody incompatible renal transplantation. Indian J Nephrol (2012) 0.83
Capillary C4d and Kidney Allograft Outcome in Relation to Morphologic Lesions Suggestive of Antibody-Mediated Rejection. Clin J Am Soc Nephrol (2015) 0.83
Key role for CD4 T cells during mixed antibody-mediated rejection of renal allografts. Am J Transplant (2014) 0.82
Autoimmune Liver Disease Post-Liver Transplantation: A Summary and Proposed Areas for Future Research. Transplantation (2016) 0.81
Endothelium under stress: local and systemic messages. Semin Nephrol (2012) 0.81
Mechanism of accommodation in a sensitized human leukocyte antigen transgenic murine cardiac transplant model. Transplantation (2012) 0.80
Personalization of the immunosuppressive treatment in renal transplant recipients: the great challenge in "omics" medicine. Int J Mol Sci (2015) 0.80
Activation of intrarenal complement system in mouse model for chronic cyclosporine nephrotoxicity. Yonsei Med J (2007) 0.78
Emerging role of B cells in chronic allograft dysfunction. Kidney Int Suppl (2010) 0.78
Significance of intragraft CD138+ lymphocytes and p-S6RP in pediatric kidney transplant biopsies. Transplantation (2010) 0.78
The role of antibodies in transplantation. Transplant Rev (Orlando) (2009) 0.78
Complement regulation of T-cell alloimmunity. Curr Opin Organ Transplant (2011) 0.78
Capillary deposition of complement C4d and C3d in Chinese renal allograft biopsies. Dis Markers (2015) 0.77
Clinical and pathological features of kidney transplant patients with concurrent polyomavirus nephropathy and rejection-associated endarteritis. World J Transplant (2015) 0.77
Complement activation in kidney transplantation: from risk stratification to therapeutic strategies. Clin Exp Immunol (2014) 0.77
Behaviour of non-donor specific antibodies during rapid re-synthesis of donor specific HLA antibodies after antibody incompatible renal transplantation. PLoS One (2013) 0.76
The Complement System and Antibody-Mediated Transplant Rejection. J Immunol (2015) 0.76
[The discovery of capillary Cd4 in kidney transplantation and the "renaissance" of humoral rejection]. Wien Klin Wochenschr (2006) 0.76
One-year protocol biopsies from ABO-incompatible renal allografts compared with a matched cohort of ABO-compatible allografts. Clin Transplant (2015) 0.75
The diagnostic value of transcription factors T-bet/GATA3 ratio in predicting antibody-mediated rejection. Clin Dev Immunol (2013) 0.75
Acute Rejection Phenotypes in the Current Era of Immunosuppression: A Single-Center Analysis. Transplant Direct (2017) 0.75
[Alloantibodies-mediated kidney transplant rejection: a pair of continuing approaches, and with nonetheless many open questions]. Wien Klin Wochenschr (2006) 0.75
The Banff 97 working classification of renal allograft pathology. Kidney Int (1999) 9.02
Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant (2008) 8.09
Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest (1981) 6.89
Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant (2007) 5.39
Occludin is a functional component of the tight junction. J Cell Sci (1996) 3.90
Intercellular adhesion molecule-1-deficient mice are protected against ischemic renal injury. J Clin Invest (1996) 3.73
Synthesis of the second component of complement by long-term primary cultures of human monocytes. J Exp Med (1976) 3.64
Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts. N Engl J Med (1981) 3.63
Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant (2014) 3.43
Myeloma responses and tolerance following combined kidney and nonmyeloablative marrow transplantation: in vivo and in vitro analyses. Am J Transplant (2006) 3.34
Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant (2010) 3.29
Mixed allogeneic chimerism and renal allograft tolerance in cynomolgus monkeys. Transplantation (1995) 3.18
International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int (1993) 3.11
Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC125. Int J Gynecol Pathol (1983) 2.90
Identification of the CD4(+) T cell as a major pathogenic factor in ischemic acute renal failure. J Clin Invest (2001) 2.79
Role of the clotting system in cell-mediated hypersensitivity. I. Fibrin deposition in delayed skin reactions in man. J Exp Med (1973) 2.75
Structural and functional regulation of tight junctions by RhoA and Rac1 small GTPases. J Cell Biol (1998) 2.75
Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med (2000) 2.61
Diagnosis and management of renal cell carcinoma. A clinical and pathologic study of 309 cases. Cancer (1971) 2.56
A study of Complement Fixation in Syphilis with Treponema Antigens. J Med Res (1913) 2.46
Immunohistologic and immunoelectron microscopic characterization of the mucosal lymphocytes of human small intestine by the use of monoclonal antibodies. J Immunol (1983) 2.44
Expression of heme oxygenase-1 can determine cardiac xenograft survival. Nat Med (1998) 2.40
Clonal dominance among T-lymphocyte infiltrates in arthritis. Proc Natl Acad Sci U S A (1988) 2.36
Widespread and selective induction of major histocompatibility complex-determined antigens in vivo by gamma interferon. J Exp Med (1985) 2.34
Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid, and clear cell types. Am J Clin Pathol (1983) 2.33
Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci U S A (1998) 2.29
Banff 2011 Meeting report: new concepts in antibody-mediated rejection. Am J Transplant (2012) 2.28
Antibody to intercellular adhesion molecule 1 protects the kidney against ischemic injury. Proc Natl Acad Sci U S A (1994) 2.26
Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation. Lancet (1999) 2.26
Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation (1981) 2.22
Guideline for infection control in healthcare personnel, 1998. Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol (1998) 2.20
Role of platelet-derived growth factor in wound healing: synergistic effects with other growth factors. Proc Natl Acad Sci U S A (1987) 2.17
A novel pathway of chronic allograft rejection mediated by NK cells and alloantibody. Am J Transplant (2011) 2.16
Combined histocompatibility leukocyte antigen-matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal disease: the induction of allograft tolerance through mixed lymphohematopoietic chimerism. Transplantation (1999) 2.16
Effective treatment of lymphedema of the extremities. Arch Surg (1998) 2.11
Fibronectin and fibrin provide a provisional matrix for epidermal cell migration during wound reepithelialization. J Invest Dermatol (1982) 2.10
Safety of revaccination with pneumococcal polysaccharide vaccine. JAMA (1999) 2.09
Pretransplant IgG reactivity to apoptotic cells correlates with late kidney allograft loss. Am J Transplant (2014) 2.09
Native portal vein embolization for persistent hyperoxaluria following kidney and auxiliary partial liver transplantation. Am J Transplant (2013) 2.05
Growth factors in wound healing. Single and synergistic effects on partial thickness porcine skin wounds. J Clin Invest (1989) 2.04
The immunopathology of experimental allergic encephalomyelitis. II. Endothelial cell Ia increases prior to inflammatory cell infiltration. J Immunol (1984) 2.02
VIP17/MAL, a lipid raft-associated protein, is involved in apical transport in MDCK cells. Proc Natl Acad Sci U S A (1999) 2.00
Evidence for a pathogenic role of a cell-mediated immune mechanism in experimental glomerulonephritis. J Exp Med (1978) 1.98
Kidney transplants in mice. An analysis of the immune status of mice bearing long-term, H-2 incompatible transplants. J Exp Med (1978) 1.95
Mixed chimerism and tolerance without whole body irradiation in a large animal model. J Clin Invest (2000) 1.86
Changing pattern of organ donation at a single center: are potential brain dead donors being lost to donation after cardiac death? Am J Transplant (2010) 1.84
Controlled clinical trial of prophylactic human-leukocyte interferon in renal transplantation. Effects on cytomegalovirus and herpes simplex virus infections. N Engl J Med (1979) 1.83
Influenza vaccination programs for elderly persons: cost-effectiveness in a health maintenance organization. Ann Intern Med (1994) 1.79
Glomerulopathy associated with cytomegalovirus viremia in renal allografts. N Engl J Med (1981) 1.77
Restoration of tight junction structure and barrier function by down-regulation of the mitogen-activated protein kinase pathway in ras-transformed Madin-Darby canine kidney cells. Mol Biol Cell (2000) 1.76
BK virus in solid organ transplant recipients: an emerging syndrome. Transplantation (2001) 1.75
Accessory cells of the lung. I. Interferon-gamma increases Ia+ dendritic cells in the lung without augmenting their accessory activities. Am J Respir Cell Mol Biol (1991) 1.73
Chronic humoral rejection: identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. J Am Soc Nephrol (2001) 1.72
Prognostic factors for melanoma patients with lesions 0.76 - 1.69 mm in thickness. An appraisal of "thin" level IV lesions. Ann Surg (1982) 1.72
Ultra-late recurrence (15 years or longer) of cutaneous melanoma. Cancer (1997) 1.71
Morphology of delayed type hypersensitivity reactions in man. I. Quantitative description of the inflammatory response. Lab Invest (1974) 1.68
Pathological and clinical correlates of FOXP3+ cells in renal allografts during acute rejection. Am J Transplant (2007) 1.67
Preliminary description of focal segmental glomerulosclerosis in patients with renovascular disease. Lancet (1996) 1.66
Long-term outcome and alloantibody production in a non-myeloablative regimen for induction of renal allograft tolerance. Transplantation (1999) 1.66
Bi-specific monoclonal antibodies: selective binding and complement fixation to cells that express two different surface antigens. J Immunol (1987) 1.64
Thymic transplantation in miniature swine. I. Development and function of the "thymokidney". Transplantation (1999) 1.64
Depletion of CD8 memory T cells for induction of tolerance of a previously transplanted kidney allograft. Am J Transplant (2007) 1.64
Lymphocyte activation antigens. I. A monoclonal antibody, anti-Act I, defines a new late lymphocyte activation antigen. J Immunol (1984) 1.60
Inducible expression of claudin-1-myc but not occludin-VSV-G results in aberrant tight junction strand formation in MDCK cells. J Cell Sci (2000) 1.58
Rubella seropositivity in the United States, 1988-1994. Clin Infect Dis (2001) 1.57
Plasma exchange and tacrolimus-mycophenolate rescue for acute humoral rejection in kidney transplantation. Transplantation (1998) 1.57
Modulation of surface antigens of a human monocyte cell line, U937, during incubation with T lymphocyte-conditioned medium: detection of T4 antigen and its presence on normal blood monocytes. J Immunol (1983) 1.57
Tolerance in a concordant nonhuman primate model. Transplantation (1999) 1.53
Outcome of kidney transplantation using expanded criteria donors and donation after cardiac death kidneys: realities and costs. Am J Transplant (2007) 1.51
Prevalence of measles antibodies in asymptomatic human immunodeficiency virus-infected adults. J Infect Dis (1991) 1.50
Interaction of serum proteins with lung endothelial glycocalyx: its effect on endothelial permeability. Am J Physiol (1984) 1.49
Long-term results in recipients of combined HLA-mismatched kidney and bone marrow transplantation without maintenance immunosuppression. Am J Transplant (2014) 1.49